2. Dye Reagents

Dye Reagents

A dye is a colored substance that has an affinity to the substrate to which it is being applied.

A new approach is presented for analysis of microplastics in environmental samples, based on selective fluorescent staining using Nile Red (NR), followed by density-based extraction and filtration. The dye adsorbs onto plastic surfaces and renders them fluorescent when irradiated with blue light. Fluorescence emission is detected using simple photography through an orange filter. Image-analysis allows fluorescent particles to be identified and counted. Magnified images can be recorded and tiled to cover the whole filter area, allowing particles down to a few micrometres to be detected. The solvatochromic nature of Nile Red also offers the possibility of plastic categorisation based on surface polarity characteristics of identified particles. This article details the development of this staining method and its initial cross-validation by comparison with infrared (IR) microscopy. Microplastics of different sizes could be detected and counted in marine sediment samples. The fluorescence staining identified the same particles as those found by scanning a filter area with IR-microscopy.

Cyanine dyes can be used to quantify the amount of dsDNA within a sample. The linearity of fluorescence, as function of DNA amount of six dyes, is obtained by measuring the fluorescence intensity at the optimal excitation and emission maxima.

Dye Reagents (3116):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-138298A
    Trastuzumab deruxtecan 1826843-81-5 ≥99.0%
    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
    Trastuzumab deruxtecan
  • HY-D0711
    Indocyanine green 3599-32-4 ≥98.0%
    Indocyanine green (Foxgreen) is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography (Ex/Em = 785/813 nm).
    Indocyanine green
  • HY-P99016B
    Enfortumab vedotin-ejfv (solution) 1346452-25-2 ≥99.0%
    Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma.
    Enfortumab vedotin-ejfv (solution)
  • HY-14536
    Methylene Blue 61-73-4
    Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene Blue is a photosensitizer and redox agent. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.
    Methylene Blue
  • HY-D0717
    DAF-FM DA 254109-22-3 98.32%
    DAF-FM DA (Diaminofluorescein-FM diacetate) is a fluorescent probe for the detection and bioimaging of nitric oxide (NO). DAF-FM DA spontaneously crosses the plasma membrane and is subsequently cleaved by esterases to generate intracellular DAF-FM (Ex/Em=495/515 nm).
    DAF-FM DA
  • HY-B1046
    Clofazimine 2030-63-9 99.79%
    Clofazimine is an orally-active anti-mycobacterial agent with a wide range of anti-mycobacterial activity including leprosy and tuberculosis. Clofazimine exerts anti-inflammatory activities and anti-tumor activities by interfering DNA replication and inhibiting IL2 (IC50 = 1.10 ± 0.26 μM, Jurkat T) production. Clofazimine can be used in mycobacterial and cancer research.
    Clofazimine
  • HY-P99016A
    Enfortumab vedotin-ejfv 1346452-25-2
    Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma.
    Enfortumab vedotin-ejfv
  • HY-164789
    Sacituzumab tirumotecan 2768350-77-0 99.63%
    Sacituzumab tirumotecan (SKB264/MK-2870) is a TROP2 ADC. The internalization and anti-tumor activity of Sacituzumab tirumotecan are enhanced in tumor cell lines with EGFR mutations. Sacituzumab tirumotecan can be used in the research of triple negative breast cancer (TNBC), non small cell lung cancer (NSCLC) and other cancers.
    Sacituzumab tirumotecan
  • HY-P9921A
    Trastuzumab emtansine (solution) 1018448-65-1 98.27%
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer.
    Trastuzumab emtansine (solution)
  • HY-132253
    Polatuzumab vedotin 1313206-42-6 99.37%
    Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL).
    Polatuzumab vedotin
  • HY-164153
    ADC Control Human IgG1-vcMMAE (solution) 98.03%
    ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575).
    ADC Control Human IgG1-vcMMAE (solution)
  • HY-164152
    ADC Control Human IgG1-Deruxtecan (DAR 4)
    ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E).
    ADC Control Human IgG1-Deruxtecan (DAR 4)
  • HY-164152A
    ADC Control Human IgG1-Deruxtecan (DAR 8)
    ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E).
    ADC Control Human IgG1-Deruxtecan (DAR 8)
  • HY-111377
    Amine-PEG3-Biotin 359860-27-8
    Amine-PEG3-Biotin is a signal amplification label containing a biotin group and a terminal primary amine group.
    Amine-PEG3-Biotin
  • HY-19948
    Leucomethylene blue mesylate 1236208-20-0 ≥98.0%
    Leucomethylene blue (TRx0237) mesylate, an orally active second-generation tau protein aggregation inhibitor (Ki of 0.12 μM), could be used for the study of Alzheimer's Disease. Leucomethylene blue mesylate is a common reduced form of Methylene Blue, Methylene Blue is a member of the thiazine class of dyes.
    Leucomethylene blue mesylate
  • HY-171135
    Cetuximab MMAE 99.53%
    Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity.
    Cetuximab MMAE
  • HY-D0006
    Bathophenanthroline 1662-01-7
    Bathophenanthroline is a nitrogen-containing organic ligand that can form stable complexes with transition metal ions such as Ru2+. In proteomics, Bathophenanthroline is often used for in-gel protein staining. The negatively charged sulfonic acid groups of Bathophenanthroline interact electrostatically with the positively charged amino acid residues of proteins, thereby achieving specific binding to proteins and enhancing the fluorescent signal of detection. Bathophenanthroline can be used for protein separation and detection in SDS-PAGE gels in the field of proteomics, as well as other fluorescence studies[1]. Ex/Em=532 nm/610 nm[1].
    Bathophenanthroline
  • HY-171265
    MRG003
    MRG003 is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575).
    MRG003
  • HY-132253A
    Polatuzumab vedotin (solution) 1313206-42-6 98.36%
    Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL).
    Polatuzumab vedotin (solution)
  • HY-156712
    Depatuxizumab MMAE 99.73%
    Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising an anti EGFR monoclonal antibody (Depatuxizumab) (HY-P99849) and the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162). Depatuxizumab MMAE can be used for the study of EGFR-expressing advanced solid tumors.
    Depatuxizumab MMAE